Champions Oncology (CSBR) Liabilities and Shareholders Equity (2011 - 2026)

Champions Oncology's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $28.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 7.12% year-over-year to $28.4 million; the TTM figure through Jan 2026 stood at $121.5 million (up 13.62% YoY), while the FY2025 annual figure was $32.3 million, up 23.77% from the prior year.
• Liabilities and Shareholders Equity was $28.4 million for Q1 2026 at Champions Oncology, down from $30.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $36.4 million in Q4 2022 to a low of $24.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $30.8 million across 5 years, with a median of $30.5 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 32.95% in 2022, then slipped 25.9% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $36.4 million in 2022, then dropped by 22.19% to $28.3 million in 2023, then decreased by 10.79% to $25.2 million in 2024, then increased by 19.5% to $30.2 million in 2025, then fell by 5.69% to $28.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $28.4 million (Q1 2026), $30.2 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.